Latest Breaking News On - Egfr exon 20 insertion mutations - Page 1 : comparemela.com

Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Marka socinskiFirst line treatmentMutated advancedPrimary results fromRandomized phasePapillon studyPapillon trialAdvanced non small cell lung cancerAdvanced nsclcEgfr exon 20 insertion mutated advanced nsclcEgfr exon 20 insertion mutationsBispecific antibodySafety profileAmivantamab safety provile